References
- 1RossCATabriziSJHuntington's disease: from molecular pathogenesis to clinical treatment.Lancet Neurol201110839810.1016/S1474-4422(10)70245-321163446
- 2HerishanuYOParvariRPollackYet alHuntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?J Neurol Sci200927714314610.1016/j.jns.2008.11.00519059613
- 3GroenJLde BieRMFonckeEMet alLate-onset Huntington disease with intermediate CAG repeats: true or false?J Neurol Neurosurg Psychiatry20108122823010.1136/jnnp.2008.17090220145031
- 4AndrichJArningLWieczorekSet alHuntington's disease as caused by 34 CAG repeats.Mov Disord20082387988110.1002/mds.2195818307262
- 5KenneyCPowellSJankovicJAutopsy-proven Huntington's disease with 29 trinucleotide repeats.Mov Disord20072212713010.1002/mds.2119517115386
- 6BiglanKJankovicJEberlySet alLongitudinal analysis of intermediate CAGn repeat length expansion in the Prospective Huntington Disease At-Risk Observational Study (PHAROS).Mov Disord2010Suppl 2S270
- 7SemakaACreightonSWarbySet alPredictive testing for Huntington disease: interpretation and significance of intermediate alleles.Clin Genet20067028329410.1111/j.1399-0004.2006.00668.x16965319
- 8Cooperative Huntington's Observational Research Trial.www.clinicaltrials.gov (accessed September 18, 2010).
- 9Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.Mov Disord19961113614210.1002/mds.8701102048684382
- 10RawlinsMHuntington's disease out of the closet?Lancet2010376(9750)1372137310.1016/S0140-6736(10)60974-920594589
- 11HaADJankovicJExploring the correlates of intermediate CAG repeats in Huntington disease.Postgrad Med201112311612110.3810/pgm.2011.09.246621904093
- 12SquitieriFEsmaeilzadehMCiarmielloAet alCaudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene.Mov Disord20112692592710.1002/mds.2362321370274
- 13SequeirosJRamosEMCerqueiraJet alLarge normal and reduced penetrance alleles in Huntington disease: instability in families and frequency at the laboratory, at the clinic and in the population.Clin Genet20107838138710.1111/j.1399-0004.2010.01388.x20236117
- 14HendricksAELatourelleJCLunettaKLet alEstimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27–35 CAG).Am J Med Genet A2009149A1375138110.1002/ajmg.a.3290119507258
- 15GoldbergYPMcMurrayCTZeislerJet alIncreased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population.Hum Mol Genet199541911191810.1093/hmg/4.10.19118595415
- 16CurtisAMitchellIPatelSet alA pilot study using nabilone for symptomatic treatment in Huntington's disease.Mov Disord2009242254225910.1002/mds.2280919845035
- 17KieburtzKMcDermottMPVossTSet alA randomized, placebo-controlled trial of latrepirdine in Huntington disease.Arch Neurol20106715416010.1001/archneurol.2009.33420142523
- 18VaccarinoALAndersonKBorowskyBet alAn item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.Mov Disord20112687788410.1002/mds.2357421370269
- 19AzizNAvan der BurgJMLandwehrmeyerGBet alWeight loss in Huntington disease increases with higher CAG repeat number.Neurology2008711506151310.1212/01.wnl.0000334276.09729.0e18981372
- 20PatelSJankovicJHoodAet alReflexive and volitional saccades: Biomarkers of Huntington disease severity and progression.J Neurol Sci20122153131-2354122018763